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ABSTRACT
Aim: To determine the level of objectively measured moderate-to-vigorous physical activity (MVPA) in patients with
heart failure (HF), and to assess the association between MVPA and patient sociodemographic, exercise capacity, and
health status factors.
Methods: Baseline MVPA data was available in 247 HF patients with 7-day wrist-worn accelerometry from two
randomized controlled trials. Associations between MVPA and patient sociodemographic, exercise capacity, and
health status factors were assessed using univariate and multivariable linear regression models.
Results: 247 patients (28% female, mean age 71 ± 10 years) with HF with reduced ejection fraction (n=198) and
preserved ejection fraction (n=49) were included in the analysis. Average MVPA was 283. 3 min/week and ranged
widely from a minimum of 0 mins/week to maximum of 2626. 7 mins/week (standard deviation: 404. 1 mins/week).
111 (45%) of patients had a level of PA that met current guidelines of at least 150 minutes/week of MVPA.
Multivariable regression showed patient’s age, body mass index, employment status, smoking status, New York Heart
Association class, NT-proBNP and exercise capacity to be strongly associated (p<0. 001) with the level of MVPA (p<0.
001).
Conclusion: Whilst 45% of HF patients had objectively measured levels of MVPA that met current PA
recommendations, we observed a wide range in the level of MVPA across this patient sample. As a number of factors
were found to be associated with MVPA our findings provide important information for future interventions aiming
to increase MVPA in HF patients.
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INTRODUCTION
There are numerous benefits of regular physical activity (PA)
that persist across the life course, including prevention and
management of chronic disease, prolonging functionality and
increasing health-related quality of life [1]. To achieve these
health benefits, it is recommended that adults perform at least
150 minutes per week (i. e. ≥ 30 minutes/day over 5 or more
days per week) of moderate-to-vigorous PA (MVPA) [1].
A small number of studies to date have quantified the PA levels
of HF patients and consistently report daily MVPA levels much
lower than the recommended 30 minutes. Some studies have
reported that HF patients undertake on average as little as 1
minute of MVPA per day [2-5]. However, these previous studies
are limited by small sample sizes (N<100), [2-4] and/or reliance
on self-report measures of PA, [5] which have been shown to be
less reliable than objective measures [6]. Moreover, studies that
did use objective PA methods are based on proprietary
algorithms that assess levels of MVPA from data in healthy
adults.
The aims of this study were to: (1) Determine the level of
objectively measured PA and MVPA in HF patients using HF-
specific intensity algorithms and (2) Assess the association
between MVPA and patient sociodemographic, exercise capacity,
and health status factors.
METHODS
Study design
This study used baseline data pooled from two randomized
controlled trials of a home-based cardiac rehabilitation
intervention for HF patients (REACH-HF): a single centre study
in patients with HF with preserved ejection fraction (HFpEF)
(ISRCTN78539530)and a multicenter study in patients in HF
reduced ejection fraction (HFrEF) (ISRCTN86234930)[7-10].
Both trials were conducted in accord with the principles of the
Declaration of Helsinki and ethical approval was granted by the
East of Scotland Research Ethics Service (15/ES/0036) [9] and
by the North West Lancaster Research Ethics Committee
(14/NW/1351) [10].
Study participants
Participating HF patients were recruited from primary and
secondary care settings in five UK centres (Birmingham,
Cornwall, Dundee, Gwent, and York) between January 2015
and February 2016 [9,10]. A total of 266 patients completed the
baseline visit, 216 with HFrEF(defined as left ventricular
ejection fraction<45%) and 50 with HFpEF (defined as left
ventricular ejection fraction ≥ 45%). The patients were aged ≥ 18
years and had a confirmed diagnosis of HF on echocardiography
or angiography within the last 6 months [7,8]. A full list of trial
inclusion and exclusion criteria are provided in supplementary
file A. All study participants provided written informed consent.
Data collection
Medical history, demographics, blood test, and exercise
capacity: During their baseline clinic visit the following
categories of data were collected: (1) Medical history, i. e.
comorbidities, New York Heart Association (NYHA) class, HF
aetiology, concomitant HF medication and presence of
implantable cardiac devices; (2) Sociodemographic information
i. e. age, ethnicity, weight, employment status, and smoking
status; (3) Blood sample was taken for measurement of N-
terminal Brain Natriuretic Peptide (NT-proBNP); (4) Health
outcome questionnaires –  i. e. disease-specific health-related
quality of life assessed by Minnesota Living with Heart Failure
Questionnaire, and the Health Related Quality of Life
(HeartQoL) questionnaire; psychological wellbeing using the
Hospital Anxiety and Depression Scale questionnaire; generic
health-related quality of lifeusing the EQ-5D-5L questionnaire;
and Self-care of HF Index questionnaire; (5) Exercise capacity
assessed by an incremental shuttle walk test (ISWT) – the ISWT
was performed twice with at least 30 minutes rest between the
tests, administered by the PI or research nurse. Standardized
instructions were given to patients, and no encouragement was
given throughout the test [7,8]. The peak distance (m) walked in
either of the two tests was recorded.
Physical activity accelerometry
At baseline visit, patients were also provided a GENEActiv triaxial
accelerometer (GENEActiv, Activinsights, Kimbolton,
Cambridge, UK) and instructed to wear the accelerometer on
their non-dominant wrist for 7 days during waking and sleeping
hours [9,10]. Monitors were returned using postage-paid
envelopes. Data were downloaded using GENEActiv PC
software (version 3. 2; Activ insights, Kimbolton, Cambridge,
UK) and analysed in R (R Core Team, Vienna, Austria) using
the GGIR software package (version 1. 5-18, ). Initial processing
included auto calibration, the detection of abnormally high
values and non-wear [11,12]. Data were averaged over 5 second
epochs and Euclidean Norm Minus One was used to quantify
the acceleration related to movement registered and was
expressed in units of milligravity (mg) [13]. The Euclidean norm
(magnitude) of the 3 raw signals minus 1000 mg, with negative
numbers rounded to zero was calculated using the following
formula:
Non-wear was determined over 60 minute windows using 15
minute increments, and was apparent when 2 of the 3 axes had
a data range<50 mg and a standard deviation<13 mg[14]. To be
included in analysis patients were required to have ≥ 16 hours
per day and ≥ 7 days of wear. The first seven days that met the
criteria were used for analysis.
For each patient, the following PA metrics were calculated: (1)
minutes per week of MVPA,(2) whether patients meet the PA
recommendation of ≥ 150 minutes of MVPA per week, (3)
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average daily PA levels (over all days, weekdays only, and
weekend days only) broken down into minutes of inactivity, light
PA, and MVPA. These metrics were calculated usingHF
population specific accelerometer intensity thresholds for
inactivity of 16. 7 mg (left wrist) and 18. 6 mg (right wrist) and
MVPA of 43. 6 mg (left wrist) and 45. 5 mg (right wrist). These
intensity thresholds were determined by a recent calibration
study in 21 HF patients with concurrently assessed acceleration
values and directly measured oxygen uptake across a range of
activities of daily living [15]. These metrics were calculated using
both bouted PA i. e. periods of PA sustained for at least 10
minutes where accelerometer readings lie above the intensity
threshold (with a 20% allowance for values to fall outside the
threshold) and unbouted i. e. PA accumulated in bouts of any
length.
Statistical analysis
Descriptive statistics were used to summarize patient
characteristics and levels of PA. Continuous variables are
presented as means and standard deviations (SD) and discrete
variables presented as counts or percentages.
Univariate linear regression analysis was conducted to examine
the association between MVPA in minutes/week and each group
of potential predictor variables (i. e. medical history/
sociodemographics, exercise capacity, health status outcomes)
separately. Univariate logistic regression was used to examine the
association with these groups of variables and the binary
outcome of whether patients meet PA guidelines or not.
Variables were selected for multivariable analysis if there was
statistical evidence of (p<0. 15) of their association in univariate
analysis.
Three multivariable PA regression models were developed for
both MVPA in minutes/week and binary outcome of meeting
PA guidelines or not: model 1 –  medical history
sociodemographic variables only, model 2 - exercise capacity and
health status variables only, and model 3 - medical history
sociodemographic and health and disease status variables that
were identified as statistically significant (p<0. 05) in models 1
and 2. Checks and diagnostics were performed for model
assumptions, residuals, multicollinearity (variance inflation
factor) and influential observations (Cook’s distance). Akaike
information criterion and R2 values (proportion of variance
explained) were used to inform model comparison and
selection. We performed two groups of sensitivity analyses: (1)
including the patients previously excluded with high residuals
and Cook’s distances and (2) MVPA was recalculated without
the requirement for PA to be in bouts of at least 10 minutes
(bouted).
Statistical analyses were performed using Stata (V. 15. 0;
StataCorp, College Station, Texas, USA).
RESULTS
Of the 266 patients who completed baseline visits, 247 were
included in the analysis (Table 1). Overall, patients had a mean
age of 70. 9 years and were predominantly male (72%) and
NYHA class I to III (99%). Alongside differences in
medications, HFpEF patients were more likely to be older and
female, have higher BMI, live alone, have hypertension, chronic
renal impairment, arthritis and COPD, have lower generic
health-related quality of life (EQ-5D-3L). Hospital Anxiety and
Depression Scale depression scores depression, and self-care
maintenance scores, and lower ISWT distance. Four patients
had missing accelerometer data, and 15 patients were excluded
due to inadequate accelerometer wear time (<7 days of wear with
≥ 16 hours per day). Apart from a higher proportion in
employment (26 vs. 13%, p=0. 01), excluded patients were
similar to those included in the PA analysis.
Level of PA in HF patients
The average level of MVPA across the HF patients was 283. 3
mins/week. MVPA ranged widely across the study population
from minimum of 0 mins/week to maximum of 2626. 7 mins/
week (standard deviation: 404. 1 mins/week). A total of 111
(45%) patients had a level of PA that met current guidelines of
150 minutes/week of MVPA. Daily PA of HF patients
categorized by intensity, days, and bout rule is reported in Table
2. Patients undertook 40. 5 ± 57. 7 mins/day bouted MVPA and
175. 9 ± 86. 4 min/day unbouted MVPA averaged across all days
of the week. Unbouted MVPA levels were higher during the
week days compared to weekend days (p<0. 001), but bouted
MVPA levels did not differ. Levels of bouted and unbouted light
PA were higher during weekdays than weekend days (p<0. 001)
and both bouted and unbouted inactivity levels were higher at
the weekend than during the week (p<0. 001).
Table 3 summarizes the characteristics and reported MVPA
levels of HF patients in this study and across previous HF
studies. Daily MVPA levels of the HF patients in the present
study are higher than the majority of PA levels reported in
previous studies [2-5].
PREDICTORS OF PA IN HF PATIENTS
MVPA minutes per week
Univariate analyses: Supplementary Tables A and B shows the
results of the univariate linear regressions between MVPA (min/
week) and the sociodemographic, exercise capacity and health
status factors. MVPA (min/week) was positively (p<0. 05)
associated with cause of HF, smoking history, ISWT distance,
HEART QoL global and physical scores, and overall EQ-5D-3L
score. PA was negatively (p<0. 05) related to age, body mass
index (BMI), employment status, NYHA class I-III, NT-pro-BNP,
living alone, living with child>18years, diabetes, number of
comorbidities, number of cardiorespiratory-metabolic
comorbidities, taking loop diuretics, Minnesota Living with
Heart Failure Questionnaire overall, physical and emotional
scores (where lower scores indicate better QoL), and Hospital
Anxiety and Depression Scale depression scores. Variables that
were closely related to MVPA (0. 05<p<0. 15) included living
with a parent, osteoporosis, angina and taking nitrates.
Multivariable analyses: In model 1: NYHA class I-III, age, BMI,
smoking history and employment status were all included in the
final model as significant contributors, and the model
accounted for 30% of the observed variance in MVPA (Table 4).
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Two patients were removed from multivariable analysis due to
having both high residual (e=2178, e=2040) and Cook’s distance
(D=0. 07, D=0. 15).
In model 2: ISWT distance was the only significant contributor
and explained 27% of the observed variance in MVPA (Table 4).
Two patients identified with high residual (e=2288, e=2182) and
Cook’s distance (D=0. 17, D=0. 14) were removed from the
analysis.
In model 3: two patients removed with high residual (e=2202,
e=2141) and Cook ’ s distance (D=0. 10, D=0. 14). ISWT
distance, age, BMI, and smoking history remained as significant
contributors and accounted for 36% of the variance in MVPA.
The variance inflation factor ranged from 1. 1-1. 2 across the
three models indicating a low level of multi collinearity (variance
inflation factor>5 indicates a level high correlation that may be
problematic for modelling).
Including the patients with high residuals and Cook’s distances
decreased the R2 across all three models, and resulted in the
removal of employment status in model 1, and NYHA class
being replaced by smoking status in model 3. Running a model
containing all variables with p<0. 15 from the univariate analysis
produced findings consistent to model 3. Analysis with
unbouted (<10 minutes in duration) MVPA data, which
decreased R2 across all models, and NT-pro BNP replaced
employment status in model 1, no other differences were
observed.
MVPA meeting PA recommendations
Univariate analyses: Supplementary Table C shows the results
of the univariate logistic regressions between meeting PA
guidelines and the sociodemographic, exercise capacity and
health status factors. The association between meeting PA
guidelines was statistically significant with age, BMI,
employment status, NYHA class I-III, NT-proBNP, living alone,
living with partner, diabetes, number of comorbidities, number
of cardiorespiratory-metabolic comorbidities, taking
anticoagulants, taking loop diuretics, ISWT distance, Minnesota
Living with Heart Failure Questionnaire overall, physical and
emotional scores, Hospital Anxiety and Depression Scale
depression scores and overall EQ-5D-3L. Variables that were
closely related to meeting PA guidelines (0. 05<p<0. 15)
included cause of HF and trial site.
Multivariable analyses: In model 1: NYHA class I-III, NT-
proBNP level, age, and BMI were statistically significant
contributors included in the model (Table 5). One patient with
high residual (e=5. 96) was removed.
In model 2 (exercise capacity and health status variables), only
ISWT distance was included in the model, all patients were
included in this model (Table 5).
In model 3 (overall model with all variables identified in models
1 and 2), ISWT distance and NT-proBNP level were the only
significant variables included in the model, all patients were
included in this model.
Sensitivity analysis: Including the patient previously excluded
with high residuals and Cook’s distances in model 1, which
made no difference to the included variables, but decreased the
pseudo R2. Running a model containing all variables p<0. 15
made no difference to the included variables but decreased the
pseudo R2.
Table 1: Sociodemographic characteristics and disease and health status factors at baseline of patients included in the analysis. N (%) unless
otherwise stated.
Characteristic
All patients HFrEF patients HFpEF patients
N=247 patients N=198 N=49
Mean (SD) age (years) 70. 9 (10. 4) 70. 1 (10. 7) 74. 3 (8. 0)**
Female sex 70 (28) 43 (22) 27 (55)***
Median (IQR) BMI (kg/m2) 29. 2 (25. 9-33. 6) 25. 4 (28. 1-32. 2) 31. 2 (27. 4-36. 5)**
Employment status    
Retired 199 (81) 153 (77) 46 (94)
In employment or self-employment 31 (12) 30 (15) 1 (2)
Other 17 (7) 15 (7) 2 (4)
Ethnic origin    
White 236 (96) 187 (94) 49 (100)
Other 11 (4) 11 (6) 0 (0)
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NYHA class    
I 40 (16. 2) 38 (19) 2 (4)
II 147 (59. 5) 117 (59) 30 (61)
III 59 (23. 9) 42 (21) 17 (35)
IV 1 (0. 4) 1 (1) 0 (0)
Median (IQR) LVEF (%) 35 (30-44) 34 (25-38) 62 (58-64)***
LVEF <45% 114 (46) 144 (73) 0 (0)
LVEF>45% 43 (17) 0 (0) 44 (90)
Unknown 59 (24) 54 (27) 5 (10)
Time since HF diagnosis (years)    
<1  74 (30) 65 (33) 9 (18)
1-2 47 (19) 34 (17) 13 (27)
>2 126 (51) 99 (50) 27 (55)
Live alone 66 (27) 44 (22) 22 (45)**
Current smoker 14 (6) 10 (5) 4 (8)
Cause of heart failure    
Ischaemic 115 (47) 91 (46) 24 (49)
Non-ischaemic 116 (47) 93 (47) 23 (47)
Unknown/Not classified 16 (6) 14 (7) 2 (4)
Trial site    
Truro 56 (23) 56 (29) 0 (0)
Gwent 44 (18) 44 (22) 0 (0)
Birmingham 48 (19) 48 (24) 0 (0)
York 50 (20) 50 (25) 0 (0)
Dundee 49 (20) 0 (0) 49 (100)
Comorbidities    
Diabetes mellitus 59 (24) 44 (22) 15 (31)
Myocardial infarction 70 (28) 61 (31) 9 (18)
Hypertension 113 (46) 82 (41) 31 (63)**
Stroke 29 (12) 26 (13) 3 (6)
Asthma 28 (11) 20 (10) 8 (16)
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Chronic renal impairment 45 (18) 32 (16) 13 (27)*
Arthritis 107 (43) 77 (39) 30 (61)**
Atrial fibrillation or atrial flutter 118 (48) 99 (50) 19 (39)
COPD 27 (11) 17 (9) 10 (20)*
Depression 61 (25) 46 (23) 15 (31)
Median (IQR) Number of comorbidities 3 (2-5) 3 (2-5) 4 (3-6)
Medication    
ACE inhibitor/ARB 220 (89) 182 (92) 38 (78)*
Aldosterone antagonist 118 (48) 109 (55) 9 (18)***
Anticoagulant 114 (46) 96 (48) 18 (37)
Beta blocker 194 (79) 163 (82) 31 (63)**
Digoxin 39 (16) 33 (17) 6 (12)
Loop diuretic 170 (69) 127 (64) 43 (88)**
Nitrate 38 (15) 24 (12) 14 (29)**
Mean (SD) NT-proBNP (pg/ml) 1326. 82 (1696. 67) 1467. 58 (1809. 23) 758. 04 (952. 35)**
Mean (SD) ISWT (m) (N=232) peak 230. 4 (150. 8) 245. 3 (147. 7) 171. 9 (150. 4)**
Mean (SD) MLHFQ overall 32. 1 (23. 8) 30. 9 (23. 1) 36. 9 (26. 2)
Mean (SD) HADS    
Anxiety 5. 6 (4. 4) 5. 6 (4. 3) 5. 8 (4. 8)
Depression 4. 8 (3. 5) 4. 5 (3. 3) 5. 8 (4. 0)*
Mean (SD) HeartQoL global 1. 8 (0. 78)  1. 8(0. 74) 1. 5(0. 87)
Mean (SD) EQ-5D-3L 0. 70 (0. 26) 0. 73 (0. 24) 0. 58 (0. 30)***
Mean (SD) SCHFI    
Maintenance 54. 5 (15. 8) 55. 8 (15. 6) 49. 0 (15. 3)**
Management 40. 7 (22. 5) 41. 8 (23. 6) 38. 0 (19. 6)
Confidence 62. 7 (24. 3) 63. 6 (24. 3) 59. 2 (24. 1)
SD: Standard Deviation; IQR: Interquartile Range; BMI: Body Mass Index; NYHA: New York Heart Association; HF: Heart Failure; Hfref: Heart
Failure With Reduced Ejection Fraction; Hfpef: Heart Failure With Preserved Ejection Fraction; LVEF: Left Ventricular Ejection Fraction; NT-
Probnp: NT-Pro-Brain Natriuretic Peptide; COPD: Chronic Obstructive Pulmonary Disease; ACE: Angiotensin-Converting Enzyme; ARB:
Angiotensin II Receptor Antagonist; ISWT: Incremental Shuttle Walk Test; MLHFQ: Minnesota Living With Heart Failure Questionnaire; HADS:
Hospital Anxiety And Depression Scale; SCHFI: Self-Care Of Heart Failure Index.
*p<0. 05, **p<0. 01, ***p<0. 001 HFpEF vs. HFrEF groups.
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All Days Weekend Days Week Days
Bouted*
Inactivity 1199. 6 (145. 7) 1214. 5 (150. 4) 1193. 6 (150. 9)***
Light PA 200. 0 (108. 0) 187. 9 (114. 1) 204. 8 (112. 2)***
MVPA 40. 5 (57. 7) 37. 6 (58. 7) 41. 6 (60. 5)
Unbouted†
Inactivity 1075. 1 (110. 1) 1089. 3 (115. 7) 1069. 4 (113. 1)***
Light PA 189. 0 (46. 8) 183. 0 (50. 9) 191. 4 (48. 4)***
MVPA 175. 9 (86. 4) 167. 7 (86. 6) 179. 1 (89. 2)***
PA: Physical Activity; MVPA: Moderate-To-Vigorous Physical Activity.
*Bouted: Activity Accumulated In Continuous 10 Minute
Duration, †Unbouted: Activity Accumulated in Any Duration
*** p<0. 001 t-test weekend days vs. week days
Table 3: Summary of studies reporting MVPA levels of patients with heart failure.
Lead study author (year),
country
N patients included PA measurement method Level of MVPA (minutes/
day)




N=68, mean age 62 ± 14
years, 71% male, NYHA I-II
60%, NYHA III 40%
Accelerometer –  Sense
Wear Pro3 Armband worn
for 2 consecutive weekdays
Mean 53 ± 54 min/day 56%
Yates (2017),
USA [3]
N=29, median age 74 (range
61-85) years, 65% male,
NYHA not reported
Modified 7 day physical
activity recall questionnaire
(self-report).
Accelerometer –  Actiheart
worn for 7 consecutive days
Not reported (self-report)





Yavari (2017), Canada [4] HFpEF N=53 , Median age
75 (IQR 66-81) years, 58%
male, NYHA I-II 75%,
NYHA III 23%.
HFrEF N=16
Median age 72. 5 (IQR
63-81) years, 81% male,
NYHA I-II 75%, NYHA III
25%
Accelerometer –  Sense
Wear Mini Armband worn
for 4 consecutive days
HFpEF – median 12 (first
quartile-third quartile 6-30)
mins/day















question “ What has the
subject ’ s usual pattern of
exercise been during the
past 2 weeks? ”  for 3
categories of activity (heavy,
medium, light)
Not reported 11%
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Table 2: Mean (sd) PA mins/day of different intensity (inactivity, Light PA, MVPA) over all days, weekend days and week days.
Present study N=247, mean age 70. 9 ±





GENEActiv worn for 7
consecutive days
mean 40. 5 ± 57. 7 min/day 45%
HF: Heart Failure; PA: Physical Activity; MVPA: Moderate-Vigorous Physical Activity; Hfpef: Heart Failure With Preserved Ejection Fraction; Hfref:
Heart Failure With Reduced Ejection Fraction.
* i. e. 150 minutes per week MVPA or 30 min/day MVPA




t-statistic Variable P-value Model Adjusted
R2 (p-value)
Socio-demographic NYHA class -133. 06 (-196. 85 to-69. 26) -4. 11 <0. 001 0. 30
(<0. 001)
Age -13. 36 (-17. 25 to-9. 47) -6. 77 <0. 001
BMI -13. 50 (-20. 06 to-. 94) -4. 05 <0. 001
Smoking history 84. 41 (19. 49 to 149. 32) 2. 56 0. 011
Employment status -40. 94 (-81. 66 to-0. 22) -1. 98 0. 049
constant 1786. 0 (1348. 48 to 2223. 52) 8. 04 <0. 001
Exercise capacity and health
status
ISWT peak 1. 2 (0. 94 to 1. 46) 9. 06 <0. 001 0. 27
(<0. 001)
constant -12. 62 (-85. 00 to 59. 76) -0. 34 0. 73
Socio-demographic, exercise
capacity and health status*
ISWT peak 0. 84 (0. 57 to 1. 11) 6. 17 <0. 001 0. 36
(<0. 001)
Age -10. 55 (-14. 39 to-6. 71) -5. 41 <0. 001
BMI -11. 17 (-17. 54 to-4. 80) -3. 45 0. 001
Smoking history -65. 09 (2. 11 to-128. 07) 2. 04 0. 04
constant 1001. 40 (560. 16 to 1442. 63) 4. 47 <0. 001
PA: Physical Activity; NYHA: New York Heart Association; BMI: Body Mass Index; NT-proBNP: NT-pro-brain Natriuretic Peptide; ISWT:
Incremental Shuttle Walk Test
* All variables p<0. 05 from multivariate models 1 and 2.
Multivariable model Variables included in
model (p<0.05)
OR (95% CI) z-statistic Variable P-value Model Pseudo
R2 (p-value)
Socio-demographic NYHA 0.39 (0.23 to 0.66) -3.51 <0.001 0.18
(<0.001)
NT-proBNP 1.00 (1.00 to 1.00) -3.76 <0.001
Age 0.96 (0.93 to 0.99) -2.90 0.004
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Table 4: Comparison of multivariable linear regression models to predict minutes/week PA.
Table 5: Comparison of multivariable logistic regression models to predict meeting PA guidelines.
BMI 0.93 (0.88 to 0.98) -2.56 0.01
Constant 2235.99 (103.71 to 48209.83) 4.92 <0.001
Exercise capacity and health
status
ISWT peak 1.01 (1.00 to 1.01) 5.17 <0.001 0.11 (<0.001)
constant 0.21 (0.12 to 0.38) -5.18 <0.001
Socio-demographic, exercise
capacity and health status*
ISWT peak 1.01 (1.00 to 1.01) 5.00 <0.001 0.15 (<0.001)
NT-proBNP 1.00 (1.00 to 1.00) -3.07 0.002
Constant 0.34 (0.18 to 0.65) -3.31 0.001
PA: Physical Activity; NYHA: New York Heart Association; BMI: Body Mass Index; NT-proBNP: NT-pro-brain Natriuretic Peptide; ISWT:
Incremental Shuttle Walk Test
* All variables p<0. 05 from multivariate models 1 and 2.
DISCUSSION
We found that some 45% of HF patients had objectively
assessed levels of activity that meet current recommendations of
at least 150 minutes per week of MVPA. HF patients undertook
an average of 283. 3 min/week MVPA. However, the level of
MVPA across patients ranged widely from a minimum of 0
mins/week to a maximum of 2626. 7 mins/week. Results also
showed that HF patients have higher levels of MVPA and light
PA, and lower levels of inactivity during the week compared to
the weekends.
Our results differ somewhat from the majority of previous
studies reporting very low levels of MVPA in HF patients [3-5].
However, these previous studies have relied on less accurate
methods of measuring PA intensity, either using self-reported
measures, or categorising accelerometer measured PA intensity
using thresholds derived from studies of healthy adults. In this
study, we used recently developed HF specific accelerometer
intensity thresholds for MVPA to determine MVPA levels of HF
patients. Using HF population specific accelerometer intensity
thresholds provides a more accurate estimation of PA intensity
as the increased energy cost of physical activities and limited
exercise tolerance of HF patients are taken into account. Were
we to have used the standard thresholds [16,17], it would have
been concluded that HF patients undertook 33. 2 ± 74. 1 mins/
week MVPA, and only 19 (8%) of patients met PA guidelines of
150 minutes of MVPA/week.
The three multivariable linear regression models, and three
multivariable logistic regression models revealed that lower PA
levels were associated with older patients, those with higher
BMI, patients who were unemployed, higher NYHA classes,
current smokers, higher NT-pro BNP levels, and lower ISWT
peak distances. Since PA has been shown to have stronger
associations with mortality in HF patients than measures of
physical fitness [18], these variables may be useful for clinicians
to identify those patients for whom PA promoting interventions
may be most beneficial, and to tailor the information, PA and
exercise plans provided, as recommended in current cardiac
rehabilitation guidelines [19,20].
Our results build up on previous studies that showed PA is
associated with a number of HF patient clinical characteristics
[18, 21-25]. Previous studies have also shown that patients with
lower PA levels had a higher burden of comorbidities [18]. In
our univariate analyses, we found that apart from diabetes, the
presence of other comorbidities in isolation were not associated
with PA level. However, the total number of comorbidities was
significantly associated with PA level. We found that the number
of cardiorespiratory and metabolic comorbidities was associated
with PA whereas the number of physical and musculoskeletal
was not associated with PA. We also confirm that reduced PA is
moderately associated with reduced exercise capacity in HF
patients, with ISWT peak distance giving the highest univariate
R2 value.
Strengths and limitations
Our study has a number of strengths. We believe this to be the
first study objectively assessed PA levels of HF patients using
accelerometry and HF-specific intensity thresholds, That PA is
measured and reported using a range of methods and metrics
makes direct comparison across studies difficult [26]. It is
common practice to estimate levels of MVPA from
accelerometer data using previously reported PA intensity
thresholds, or proprietary, private algorithms from commercially
available activity monitors [15-17,27]. However, these thresholds
and algorithms are based on studies using young, healthy adults,
therefore may not be applicable to chronic disease or elderly
populations [15,28]. As HF patients have limited exercise
capacity, the energy cost of physical activities are higher,
[15,29]so applying these intensity thresholds risks
misclassification of PA of HF patients, which is highlighted by
our previous comment on MVPA conclusions, had we used the
standard intensity thresholds. Using improved MVPA
assessment methods, with HF specific intensity thresholds as a
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potentially more accurate measure in this patient population
should provide more precise understanding of the relationships
between sociodemographics, exercise capacity, and health and
disease status factors and PA levels of HF patients. This study
also benefits from a relatively large HF patient sample from two
clinical and recruited from a number of sites across UK [9,10].
Our study also has some limitations. Because of tolerability,
dose of medication was not optimized in all patients. Although
each of the multivariable models identified factors with
significant associations with PA, over 50% of the variance in
MVPA mins/week remained unexplained. Studies have
identified motivation, exercise self-efficacy and fear of PA to be
barriers to PA in HF patients although these were not assessed
in this study [30,31]. Sedentary time has been shown to be a risk
factor for poor outcomes in cardiac rehabilitation participants
independent of PA level [32]. Inclusion of heart rate data has
also been shown to improve accuracy of energy expenditure
estimation [33]. Future studies may consider measurement of
these additional factors in order to improve PA prediction
models.
Although our study sample size was larger than previously
reported studies of PA levels in HF patients and associations
with various factors in HF [18, 25],the frequency count of some
of the demographic variables was low such as ethnic minorities,
presence of some comorbidities and taking particular
medications. Given the cross-sectional nature of this study, the
associations found between PA and sociodemographics, exercise
capacity and health status factors cannot be implied to be causal.
Longitudinal studies of objectively assessed PA in HF patients
using population specific accelerometer intensity thresholds are
needed to confirm the results of the present study.
CONCLUSIONS
Almost half of the HF patients in this study had objectively
assessed levels of MVPA that met current PA recommendations
of at least 150 minutes per week of MVPA. However, we also
found the level of MVPA to range widely across patients in our
study. Patients were less inactive and performed more PA during
the week compared to the weekend. Multivariable regression
analyses showed that patient age, BMI, employment status,
NYHA class I-III, current smoking status, NT-pro BNP level, and
ISWT peak distance to be strongly associated with the PA levels
of HF patients. These factors may be useful to help inform
clinicians and researchers how best to target subgroups of HF
patients who could most benefit from interventions to increase
their PA. Future accelerometry studies of PA in chronic disease
populations need to consistently apply population specific
thresholds when estimating MVPA.
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